On January 30, 2013, the Board of Directors
(the “Board”) of Arno Therapeutics, Inc. (the “Company”) appointed Randy Thurman as a director of the Company. Mr.
Thurman, age 63, is an Operating Executive at AEA Investments LP, a private equity firm. Before joining AEA in October 2012, Mr.
Thurman had been a Senior Advisor at New Mountain Capital, LLC, a private and public equity investment firm, since May 2008. From
July 2008 to October 2011, Mr. Thurman served as a director of CardioNet, Inc. (NASDAQ:BEAT), a global leader in ambulatory cardiac
monitoring and diagnosis, where he also served as Executive Chairman from July 2008 to January 2009, as President and Chief Executive
Officer from February 2009 to June 2010, and as Chairman from June 2009 until his resignation from the board of directors in October
2011. From July 2007 through June 2008, Mr. Thurman served as a consultant to Cardinal Health, Inc., a global healthcare
provider, following Cardinal Health’s July 2007 acquisition of VIASYS Healthcare Inc., a healthcare technology company
at which Mr. Thurman had served as Chief Executive Officer since April 2001. Mr. Thurman currently serves as Executive Chairman
of Cogent HMG, a national leader in the fields of hospital medicine and critical care medicine, and as a director of Allscripts
Healthcare Solutions, Inc. (NASDAQ:MDRX), a healthcare information technology company. Mr. Thurman received a B.S. in Economics
from Virginia Polytechnic Institute and an M.A. in Economics from Webster University. There are no family relationships between
Mr. Thurman and any other member of the Board or any executive officer of the Company.

As consideration for his service on the
Board, Mr. Thurman will receive an annual cash stipend of $50,000, payable quarterly in arrears. In addition, Mr. Thurman was granted
a 10-year option (the “Option”) to purchase 200,000 shares of the Company’s common stock at an exercise price
of $0.30 per share. The right to purchase one-third of the shares subject to the Option vested immediately and the remaining shares
subject to the Option will vest and become exercisable in two equal annual installments on the first and second anniversaries of
Mr. Thurman’s appointment. The Option was granted pursuant to the Company’s 2005 Stock Option Plan, as amended (the
“Plan”), and is evidenced by a stock option agreement in the Company’s standard form for use under the Plan.
Mr. Thurman will also receive additional option grants on an annual basis, consistent with the Board’s compensation plan
for non-employee directors. A copy of the letter agreement setting forth the terms of Mr. Thurman’s compensation as a director
is attached hereto as Exhibit 10.1 and incorporated herein by reference.

Site Links

Based on public records. Inadvertent errors are possible. Getfilings.com does not guarantee the accuracy or timeliness of any information on this site. Use at your own risk.
This website is not associated with the SEC.